含泽布替尼一线方案治疗弥漫大B细胞淋巴瘤的临床观察  

The Clinical Observation of Frontline Treatment in Combination with Zanubrutinib for Diffuse Large B-cell Lymphoma

在线阅读下载全文

作  者:李俊 胡丽娜 邱骁 孙熊滨 周继豪[1,2] LI Jun;HU Li-na;QIU Xiao;SUN Xiong-bin;ZHOU Ji-hao(The Second Clinical Medical College of Jinan University,Shenzhen 518000,Guangdong Province,China;Department of Hematology,Shenzhen People’s Hospital,Shenzhen 518000,Guangdong Province,China;Department of Internal Medicine,Dongyuan County People's Hospital,Dongyuan 517500,Guangdong Province,China)

机构地区:[1]暨南大学第二临床医学院,广东深圳518000 [2]深圳市人民医院血液内科,广东深圳518000 [3]东源县人民医院内科,广东东源517500

出  处:《罕少疾病杂志》2025年第3期156-158,164,共4页Journal of Rare and Uncommon Diseases

基  金:河源市社会发展科技计划项目(241031161472608)。

摘  要:目的 探讨以泽布替尼联合化疗一线治疗弥漫大B细胞淋巴瘤的临床疗效以及安全性。方法 回顾性分析深圳市人民医院2020年8月至2024年6月接受泽布替尼联合化疗一线治疗的10例弥漫大B细胞淋巴瘤患者的临床特征、治疗反应、预后以及安全性。结果 10例患者中位年龄61.5岁(39~86岁),女性为主(8例),8例(80%)起病时存在结外侵犯。所有患者接受泽布替尼联合化疗的一线治疗,10例患者治疗中期评估显示,8例CR,1例PR,1例PD。一线治疗结束评估显示:9例CR,1例原中期评估PD患者因新冠死亡。所有患者CR率和ORR率均为90%。中位随访15.7(95%CI 11.5~19.9)个月,9例CR患者中,1例患者在缓解状态下因感染新冠死亡;其他8例患者仍持续无病生存中。安全性可控且无治疗相关死亡。结论 泽布替尼联合化疗一线治疗弥漫大B细胞淋巴瘤疗效肯定且安全性好,值得进一步探索。Objective To investigate the clinical efficacy and safety of Zanubrutinib combined with first-line chemotherapy in the treatment of diffuse large B-cell lymphoma(DLBCL).Methods The clinical features,therapeutic response,prognosis,and safety of 10 patients with DLBCL who received first-line treatment with Zanubrutinib combined with chemotherapy in Shenzhen People's Hospital from August 2020 to June 2024 were retrospectively analyzed.Results The median age of the 10 patients was 61.5 years old(39-86 years old),the majority of whom were female(8 cases),and 8 cases(80%)had extra-nodal involvement at the onset of the disease.All patients received first-line treatment with Zanubrutinib combined with chemotherapy,and were evaluated in midterm,with 8 CR,1 PR,and 1 PD.The evaluation at the end of first-line treatment showed that 9 patients with CR and 1 patient with PD originally assessed in the interim died due to COVID-19.The CR rate and ORR rate of all patients were 90%.After a median follow-up of 15.7(95%CI,11.5 to 19.9)months,among the 9 patients with CR,1 patient died of COVID-19 infection in remission;the other 8 patients are still alive without relapse.Safety is controllable and there were no treatment-related deaths.Conclusion The efficacy and safety of Zanubrutinib combined with chemotherapy in the first-line treatment of DLBCL are promising and worthy of further exploration.

关 键 词:弥漫大B细胞淋巴瘤 泽布替尼 一线治疗 

分 类 号:R733.4[医药卫生—肿瘤]

 

参考文献:

正在载入数据...

 

二级参考文献:

正在载入数据...

 

耦合文献:

正在载入数据...

 

引证文献:

正在载入数据...

 

二级引证文献:

正在载入数据...

 

同被引文献:

正在载入数据...

 

相关期刊文献:

正在载入数据...

相关的主题
相关的作者对象
相关的机构对象